40,477 Shares in LivaNova PLC (NASDAQ:LIVN) Purchased by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC bought a new position in LivaNova PLC (NASDAQ:LIVN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 40,477 shares of the company’s stock, valued at approximately $2,127,000. Segall Bryant & Hamill LLC owned about 0.07% of LivaNova as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Fifth Third Bancorp raised its holdings in shares of LivaNova by 97.1% during the second quarter. Fifth Third Bancorp now owns 674 shares of the company’s stock valued at $37,000 after purchasing an additional 332 shares during the last quarter. Hexagon Capital Partners LLC raised its stake in LivaNova by 117.8% during the 2nd quarter. Hexagon Capital Partners LLC now owns 684 shares of the company’s stock valued at $37,000 after buying an additional 370 shares during the last quarter. Lazard Asset Management LLC bought a new position in shares of LivaNova during the 1st quarter valued at $84,000. Canada Pension Plan Investment Board purchased a new position in shares of LivaNova in the 2nd quarter worth $88,000. Finally, Acadian Asset Management LLC bought a new stake in shares of LivaNova in the first quarter worth $94,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on LIVN shares. The Goldman Sachs Group started coverage on LivaNova in a report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. StockNews.com cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 16th. Robert W. Baird boosted their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. Mizuho decreased their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and set a $75.00 price objective on shares of LivaNova in a research report on Tuesday, November 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Stock Performance

Shares of NASDAQ LIVN opened at $51.32 on Friday. The stock has a market cap of $2.79 billion, a PE ratio of 122.19 and a beta of 1.01. LivaNova PLC has a 1 year low of $42.75 and a 1 year high of $64.47. The firm has a fifty day moving average price of $52.13 and a 200-day moving average price of $52.52. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

LivaNova Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.